Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Share Fallers
Why the Paradigm share price is sinking lower today
Share Fallers
Why Appen, Dicker Data, Paradigm, & Zip Co shares are tumbling lower
Share Fallers
Why Cann, Novonix, Paradigm, & Tower shares are sinking lower
⏸️ Shares to Watch
Which ASX healthcare stock could become the next CSL?
⏸️ ASX Shares
3 exciting ASX healthcare shares to watch in 2020
⏸️ Shares to Watch
Paradigm Biopharmaceuticals shares are soaring. Should you buy?
Growth Shares
Why I would buy Nearmap and these ASX mid cap growth shares
Share Gainers
Why a2 Milk, Paradigm, Praemium, & Regis Resources are storming higher
Share Market News
Why the Novita Healthcare share price is still on a wild ride
Share Gainers
Why Avita Medical, Bravura, Dicker Data, & Paradigm shares are racing higher
Share Gainers
The Paradigm Biopharmaceuticals share price is up 196% in 2019
Share Market News
The Next Science share price is tanking on a trading update
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
